News & Events

Impel NeuroPharma Announces Appointment of Sheena K. Aurora, MD, As Vice President of Medical Affairs – Migraine Franchise

January 16, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the appointment of Sheena K.…

Impel NeuroPharma Announces Appointment of Adrian Adams as Chairman of The Board of Directors

January 9, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the appointment of Adrian Adams…

Impel Neuropharma Announces Publication of Narrative Review in The Journal Headache Supporting Need For Novel Formulations Of Dihydroergotamine (DHE) In Addressing Acute Treatment of Migraine

November 20, 2019 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that a narrative review of…

2 3 4